advertisement
Home » News » New Genetic Test Can Assess Alzheimer’s Risk
New Genetic Test Can Assess Alzheimer’s Risk

New Genetic Test Can Assess Alzheimer’s Risk

Predicting a person’s risk for Alzheimer’s disease is not an easy task as a multitude of genetic factors may play a role. Accordingly, a team of California researchers developed a new test that combines the effects of more than two dozen genetic variants, most associated by themselves with only a small risk of Alzheimer’s disease.

Researchers at University of California, San Francisco (UCSF) and University of California, San Diego explain that although the genetic variant APOE E4 has long been considered the strongest genetic predictor of whether someone is likely to develop Alzheimer’s, it is only carried by 10 to 15 percent of the population. Moreover, recent studies suggest its effects have been overstated.

The new test calculates a polygenic hazard score (PHS), that provide risk estimates for the remaining 85 to 90 percent of people who do not carry at least one copy of APOE E4 but still have some combination of other genetic variants that put them at risk of Alzheimer’s.

“Beyond APOE E4 by itself, our polygenic hazard score can identify cognitively normal and mildly impaired older folks who are at greatest risk for developing Alzheimer’s-associated clinical decline over time,” said Chin Hong Tan, Ph.D., a postdoctoral scholar at UCSF and first author of the paper.

The research appears in the journal in Annals of Neurology.

Investigators looked at five years of data on 1,081 subjects from the National Alzheimer’s Coordinating Center (NACC) who did not have dementia, and found the PHS test could foresee how long it would take for them to progress to Alzheimer’s dementia. The test can also forecast how steep their cognitive decline would be, even after taking into account whether they were carriers of APOE E4.

Autopsies of those who did develop Alzheimer’s showed that, even among those who did not carry a copy of the APOE E4 variant, a higher PHS was associated with a higher level of amyloid plaque — a protein aggregate that is a hallmark of Alzheimer’s — in the brain.

These patients also showed steeper declines on cognitive tests during their lifetimes. Older individuals in the highest PHS percentiles also showed the highest incidence of Alzheimer’s, which is diagnosed with cognitive tests and brain pathology, regardless of their APOE E4 status.

Many scientists now believe that rather than being a disease of aging, Alzheimer’s may be the result of a disease process that begins years, perhaps decades, before symptoms of dementia appear. This is thought by many to be one reason why so many Alzheimer’s drugs tested on older people with dementia have failed in clinical trials.

The new PHS could help in the search for ways to identify those at risk of Alzheimer’s long before they show symptoms of dementia, so they can be treated before the disease begins ravaging their brains, the researchers said.

“Our findings have strong implications for disease stratification and secondary prevention trials in Alzheimer’s, as well as direct-to-consumer genetic tests, some of which have recently received FDA clearance,” said Anders Dale, Ph.D., University of California, San Diego and co-author of the new study.

The PHS test enables researchers to calculate an age-specific risk of developing Alzheimer’s, based upon each person’s share of 31 genetic variants, plus APOE E4. The test makes its predictions by using genetic data from more than 70,000 people in the NACC database, the International Genomics of Alzheimer’s Disease Project and the Alzheimer’s Disease Genetics Consortium.

“Unlike other polygenic risk scores, the continuous PHS measure is based on a survival framework and incorporates US-based Alzheimer’s incidence rates,” said Rahul Desikan, M.D., Ph.D., an assistant professor in the Department of Radiology and Biomedical Imaging at UCSF, and co-senior author of the paper.

“Rather than a diagnostic test, PHS may serve as a genetic ‘risk factor’ for preclinical Alzheimer’s disease.”

Source: University of California, San Francisco

New Genetic Test Can Assess Alzheimer’s Risk

Rick Nauert PhD

Rick Nauert, PhDDr. Rick Nauert has over 25 years experience in clinical, administrative and academic healthcare. He is currently an associate professor for Rocky Mountain University of Health Professionals doctoral program in health promotion and wellness. Dr. Nauert began his career as a clinical physical therapist and served as a regional manager for a publicly traded multidisciplinary rehabilitation agency for 12 years. He has masters degrees in health-fitness management and healthcare administration and a doctoral degree from The University of Texas at Austin focused on health care informatics, health administration, health education and health policy. His research efforts included the area of telehealth with a specialty in disease management.

APA Reference
Nauert PhD, R. (2017). New Genetic Test Can Assess Alzheimer’s Risk. Psych Central. Retrieved on November 17, 2018, from https://psychcentral.com/news/2017/09/25/new-genetic-test-does-better-job-predicting-alzheimers/126489.html

 

Scientifically Reviewed
Last updated: 25 Sep 2017
Last reviewed: By John M. Grohol, Psy.D. on 25 Sep 2017
Published on PsychCentral.com. All rights reserved.